199 related articles for article (PubMed ID: 36828853)
1. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
[TBL] [Abstract][Full Text] [Related]
2. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
3. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Jpn J Ophthalmol; 2024 Mar; 68(2):83-90. PubMed ID: 38244172
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
[TBL] [Abstract][Full Text] [Related]
5. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
6. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
7. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
9. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept.
Barakat A; Rufin V; Tran THC
J Fr Ophtalmol; 2018 Sep; 41(7):603-610. PubMed ID: 30166233
[TBL] [Abstract][Full Text] [Related]
10. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
11. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
[TBL] [Abstract][Full Text] [Related]
12. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
13. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
14. Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration.
Kato A; Yasukawa T; Sugita I; Yoshida M; Nozaki M; Hirano Y; Kondo J; Abe T; Sugita K; Okita T; Morita H; Takase N; Ogura Y
Adv Ther; 2022 Mar; 39(3):1403-1416. PubMed ID: 35112307
[TBL] [Abstract][Full Text] [Related]
15. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
17. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
18. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.
Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S
Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299
[TBL] [Abstract][Full Text] [Related]
19. Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center.
Scupola A; Carlà MM; Boselli F; Giannuzzi F; De Filippis A; Fossataro C; Minnella AM; D'Amico G; Coppola G; Savastano MC; Sammarco MG; Rizzo S
Ophthalmologica; 2023; 246(1):58-67. PubMed ID: 36843038
[TBL] [Abstract][Full Text] [Related]
20. One-year outcome of brolucizumab for neovascular age-related macular degeneration in Japanese patients.
Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Tsukii R; Takahashi H; Kawashima H; Yanagi Y
Sci Rep; 2024 Jan; 14(1):2451. PubMed ID: 38291120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
